Orthopaedic Surgery·Rochester, NY

University of Rochester Medical Center

Signal lift6%40%+34 pp with a signal here
Allocate signal →Track an away here25-26 cycle · applicant-level
Step 2 invited
241–270
p10 – p90
Sample N
435
applicants this cycle
This cycle
no tracked aways yet
Match rate
1.8%
8 of 108 applicants
01Cohort funnelthis cycle
N = 435
Applied
435
100.0%
Invited
108
24.8%
Class size
8
1.8%
02Away rotation impact
+92pp lift
Non-rotators
8%
59 of 727
Rotators
100%
29 of 23
Interview lift
+92pp
vs not rotating

Rotators got interviewed at 100%, vs 8% for everyone else. If you can secure a rotation here, you've effectively secured the interview.

J-1 visaCategoricalResearch
Your fitUniversity of Rochester Medical Center Program

Create a free profile to see your personalized fit

Get started
Contact
SM
Program Director
Susan McDowell, MD
Email director
BS
Program Coordinator
Bonnie Schuster
Email coordinator
Training sites2 hospitals · Rochester
  • 1
    University of Rochester Medical Center
    Rochester, NY
    Primary
  • 2
    Highland Hospital of Rochester
    Rochester, NY
    Participant
Rotator reports6 reports · paraphrased
University of Rochester
hands-on
  • 19-20Rotator in 2019/20 described an academic blue-collar program with high volume, strong autonomy, two-week service blocks, and four calls during the rotation. Daily fracture sign-out, a weekly rotator lecture series, and an end-of-rotation case presentation were noted. Trauma catchment was described as one of the largest in the state.
  • 18-19Rotator in 2018/19 described variable hands-on OR experience depending on service and resident pairing, once-weekly call plus weekends with a midnight cutoff for students, and supportive academic faculty. The program was described as spine-heavy, and no interview was offered during the rotation.
U Rochester
hands-on
  • 18-19Rotator in 2018/19 described strong operative training, friendly residents, and robust clinical and translational research. Leadership emphasized post-interview communication policies, and program alumni hold positions at major academic centers.
  • 16-17Rotator in 2016/17 described a well-rounded clinical and academic program with busy trauma, major NIH funding for MSK research, and reported 100% interview rate for rotators.
  • 15-16Rotator in 2015/16 described a well-balanced academic program with top-tier ortho research funding and a grueling trauma experience. Leadership transition noted during the cycle, with continued strong fellowship placement.
  • 14-15Rotator in 2014/15 described a trauma-heavy, research-forward program with top-tier NIH funding and strong academic emphasis, in an affordable city.

Paraphrased from rotator survey responses. Names and identifying details removed.

Score rangesinvited cohort
USMLE Step 2 CK241270
180205230255280

Level 2 CE data not available

Interview rates
US MD
30%
US DO
3%
US IMG
0%
Non-US IMG
0%
Applicant origin
In-state
42%
Out-of-state
22%
Interview prepOrthopaedic Surgery
specialtyWhy orthopaedics over general surgery?★ common
clinicalDescribe an orthopaedic case that was memorable to you.★ common
specialtyWhat subspecialty are you considering? (Sports, spine, trauma, hand, joints)★ common
behavioralHow do you maintain work-life balance in a surgical specialty?
clinicalTell me about your surgical experience.★ common
personalTell me about yourself.★ common
specialtyWhy did you choose this specialty?★ common
programWhy are you interested in our program?★ common
behavioralWhat are your strengths and weaknesses?★ common
personalWhere do you see yourself in 5-10 years?★ common
Community resourcesOrthopaedic Surgery · 25-26
Save this program

Add University of Rochester Medical Center to your list

Build a personal match list. Compare programs side-by-side, see how your timing stacks against peers, and get notified when peers hear back.

Next

Calculate your match probability for Orthopaedic Surgery.

See how your profile compares across all programs.

Open calculator →

Data from NRMP 2025 Residency Explorer. Not medical advice. © 2026 Rezumab LLC.